Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Jabil Inc (JBL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Jabil Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Jabil Inc trades at $325.22 (market cap $33.65B). The key difference: Jabil Inc is far larger — about 7.5× ACADIA Pharmaceuticals Inc.'s market cap, and Jabil Inc pays a 0.1% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | JBL | |
|---|---|---|
Market Cap | $4.49B | $33.65B |
Sector | Health | Technology |
52-Week High | $28.06 | $385.50 |
52-Week Low | $20.06 | $192.49 |
Enterprise Value | $3.69B | $36.18B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
JBL trades at $338.22, down 0.9% today, with technical indicators showing a bearish trend near support at $333. The stock has demonstrated strong earnings momentum, beating estimates for three consecutive quarters, and benefits from AI infrastructure demand driving revenue growth. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target suggesting significant upside potential.
The outlook remains positive due to AI-driven growth and margin expansion, though high valuation multiples and competitive pressures present risks. Recent manufacturing expansion in India and hyperscaler customer wins support long-term growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
